Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All molnupiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMolnupiravirMolnupiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   
0 0.5 1 1.5 2+ Mortality 58% Improvement Relative Risk Death/hospitalization -127% Hospitalization -127% Molnupiravir  Inaba et al.  EARLY TREATMENT Is early treatment with molnupiravir beneficial for COVID-19? Retrospective 294 patients in Japan Higher death/hosp. (p=0.22) and hospitalization (p=0.22), not sig. c19early.org Inaba et al., Research Square, January 2023 Favors molnupiravir Favors control

Real-world data concerning the efficacy of molnupiravir in patients vaccinated against COVID-19 during the Omicron surge in Japan

Inaba et al., Research Square, doi:10.21203/rs.3.rs-2451986/v1
Jan 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Retrospective 294 consecutive patients in Japan, showing higher risk of hospitalization/death with molnupiravir, without statistical significance.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer Chamod, Hadj Hassine, Huntsman, Marikawa, Swanstrom, Waters, Zhou, Zibat. Multiple analyses have identified variants potentially created by molnupiravir Fountain-Jones, Kosakovsky Pond, Sanderson, twitter.com.
risk of death, 58.3% lower, RR 0.42, p = 1.00, treatment 0 of 84 (0.0%), control 1 of 210 (0.5%), NNT 210, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of death/hospitalization, 127.0% higher, RR 2.27, p = 0.22, treatment 5 of 84 (6.0%), control 8 of 210 (3.8%), odds ratio converted to relative risk, day 28.
risk of hospitalization, 127.0% higher, RR 2.27, p = 0.22, treatment 5 of 84 (6.0%), control 8 of 210 (3.8%), odds ratio converted to relative risk, day 28.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Inaba et al., 15 Jan 2023, retrospective, Japan, preprint, 9 authors.
This PaperMolnupiravirAll
Real-world data concerning the efficacy of molnupiravir in patients vaccinated against COVID-19 during the Omicron surge in Japan
Satoshi Inaba, Naoya Nishioka, Hisatoshi Okumura, Koshi Nakao, Yu Hattori, Shun Futamura, Tomohito Hattori, Kengo Okabe, Daichi Nishiyama
doi:10.21203/rs.3.rs-2451986/v1
Molnupiravir is among the antiviral agents used to treat COVID-19; however, reported data on the e cacy of this drug are based on results from unvaccinated patients. As such, the e cacy of molnupiravir among vaccinated patients during the B1.1.529 (Omicron) variant outbreak remains unknown. To address this issue, this study retrospectively analyzed data from 294 vaccinated patients with COVID-19 who had at least one risk factor, between May and October 2022. Patients were divided into the molnupiravir group and the control group to investigate the correlations of molnupiravir and other factors with rates of hospitalization and death (hospitalization/death) within 28 days of admission. Potential risk factors were also examined. The study ndings indicated that molnupiravir was not associated with the rate of hospitalization/death, while age ≥ 80 years, residence in a long-term care facility, and presence of chronic obstructive pulmonary disease were signi cantly associated with the rate of hospitalization/death. Although the current results suggest that the effect of vaccination in preventing severe illness against the Omicron variant is well maintained, additional studies on risk factors and outcomes are required to validate this study's ndings.
Author Contributions: NN and ND made substantial contributions to the conception of the work. HO, KN, YH, TH, and KO made signi cant contributions to the data analysis and interpretation. SI drafted the original manuscript. NN and other authors substantially contributed to the revision of the manuscript drafts. All authors have read and agreed to the published version of the manuscript. Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Local Ethical Committee of Fukuchiyama City Hospital (Code number 4-26 and date of approval: September 28, 2022). Informed Consent Statement: Patient consent was waived due to the retrospective design and the ethical guidelines. Competing Interests: The authors declare no competing interests.
References
Abdelnabi, Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants of concern in a hamster infection model, J. Infect. Dis
Agostini, Small-molecule antiviral β-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance, J. Virol
Andrews, Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant, N. Engl. J. Med
Beigel, Remdesivir for the treatment of Covid-19 -Final report, N. Engl. J. Med
Bernal, Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients, N. Engl. J. Med
Butler, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): An open-label, platformadaptive randomised controlled trial, Lancet
Cox, Wolf, Plemper, Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets, Nat. Microbiol
De, Vito, Safety and e cacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience, J. Med. Virol
Fan, SARS-CoV-2 Omicron variant: Recent progress and future perspectives, Signal Transduct. Target. Ther
Gerayeli, COPD and the risk of poor outcomes in COVID-19: A systematic review and metaanalysis, EClinicalmedicine
Hammond, Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19, N. Engl. J. Med
He, Hong, Pan, Lu, Wei, SARS-CoV-2 Omicron variant: Characteristics and prevention, Med
Iacobucci, Covid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show, BMJ
Johansen, Increased SARS-CoV-2 infection, protease, and in ammatory responses in chronic obstructive pulmonary disease primary bronchial epithelial cells de ned with single-cell RNA sequencing, Am. J. Respir. Crit. Care Med
Kamal, Ramadan, Farraj, Bahig, Ezzat, The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review, Saudi Pharm. J
Kanda, Investigation of the freely available easy-to-use software 'EZR' for medical statistics, Bone Marrow Transplant
Lauring, Clinical severity and mRNA vaccine effectiveness for omicron, delta, and alpha SARS-CoV-2 variants in the United States: A prospective observational study
Lee, Hsieh, Ko, Molnupiravir-A novel oral anti-SARS-CoV-2 agent, Antibiotics
Nealon, Cowling, Omicron severity: Milder but not mild, Lancet
Nyberg, Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron, Lancet
Pontolillo, Molnupiravir as an early treatment for COVID-19: A real life study, Pathogens
Sheahan, An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice, Sci. Transl. Med
Takashita, E cacy of antibodies and antiviral drugs against Covid-19 omicron variant, N. Engl. J. Med
Tenforde, Association between mRNA vaccination and COVID-19 hospitalization and disease severity, JAMA
Thompson, Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and omicron variant predominance -VISION network, 10 states, MMWR Morb. Mortal. Wkly Rep
Ulloa, Buchan, Daneman, Brown, Estimates of SARS-CoV-2 omicron variant severity in Ontario, Canada, JAMA
Wahl, SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801, Nature
Wen, E cacy and safety of three new oral antiviral treatment (molnupiravir, uvoxamine and Paxlovid) for COVID-19: a meta-analysis, Ann. Med
Wong, Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: A retrospective cohort study, Lancet Infect. Dis
Yoon, Orally e cacious broad-spectrum ribonucleoside analog inhibitor of in uenza and respiratory syncytial viruses, Antimicrob. Agents Chemother
Zhao, The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis, J. Med. Virol
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit